ORIC Pharmaceuticals

We are currently enrolling three phase 1 studies, which include ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance. Friedman brings to ORIC over 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics, drug discovery, pharmacology and biomarkers. Multani brings to ORIC more than 20 years of experience in oncology drug development and treatment of patients with cancer. Our board has decades of experience founding and building leading oncology companies. Dier was responsible for leading the corporate finance, accounting, information technology, global supply chain, business development, investor relations and corporate communications functions. Hoerter served as the Chief Commercial Officer of Agios Pharmaceuticals from 2016 to 2019.